未选择的骨髓增殖性肿瘤患者中ACL TOP分析仪上血管性血友病因子活性结果不一致常见,且与高分子量多聚体丢失或出血表型无相关性
研究纳入74例未选择的骨髓增殖性肿瘤(MPN)门诊患者,用ACL TOP和Acustar分析仪及凝胶电泳多聚体分析全面评估血管性血友病因子(VWF)异常,并回顾性分析临床出血数据。ACL TOP的VWF:GPIbR/VWF:Ag比值中位数0.57显著低于Acustar的0.91(P<.001),73%患者ACL TOP比值<0.7,但无患者出现高分子量多聚体丢失;临床显著出血事件占11%,与VWF检测异常无关联。
要点
- MPN患者中ACL TOP的VWF:GPIbR/VWF:Ag比值中位数0.57,显著低于Acustar的0.91(P<.001)。
- 73%患者ACL TOP比值<0.7,但凝胶电泳均无高分子量多聚体丢失。
- 临床显著出血事件占11%,与VWF检测异常无关联,通常可找到其他原因。
核心结论
- MPN患者中功能性VWF检测不一致常见,尤其是ACL TOP的VWF:GPIbR。
- 基于本有限系列,单纯VWF功能/抗原比值<0.7(「2型模式」)对出血风险预测价值差。
研究设计与样本
- 收集74例未选择的MPN门诊患者样本,用多种方法定量和定性评估VWF,并与回顾性临床出血数据分析相关联。
- VWF检测在ACL TOP和Acustar分析仪上使用HemosIL试剂进行,同时用凝胶电泳进行多聚体分析。
主要发现
- 功能性VWF检测在分析仪间不一致:ACL TOP的VWF:GPIbR/VWF:Ag比值中位数0.57(IQR 0.43-0.71),Acustar中位数0.91(IQR 0.82-1.03;P<.001)。
- ACL TOP显示不成比例的低结果,73%患者比值<0.7。
- 尽管ACL TOP比值低,但无患者经凝胶电泳出现高分子量多聚体丢失。
- 血小板计数与功能性比值在ACL TOP(R2=0.20;P<.001)和Acustar(R2=0.18;P=.0011)分析仪上均呈负相关。
- 临床显著出血事件相对常见(11%患者),但与VWF检测异常无关联,通常可识别其他原因。
关键数值与推荐
- ACL TOP的VWF:GPIbR/VWF:Ag比值中位数0.57(IQR 0.43-0.71) vs Acustar中位数0.91(IQR 0.82-1.03),P<.001。
- 73%患者ACL TOP比值<0.7。
- 血小板计数与功能性比值:ACL TOP R2=0.20(P<.001);Acustar R2=0.18(P=.0011)。
- 临床显著出血事件占11%患者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bleeding complications are common in patients with myeloproliferative neoplasms (MPNs), with a subset developing acquired von Willebrand disease. Despite this association, a wide spectrum of von Willebrand factor (VWF) abnormalities are described, and the performance of modern assays remains unclear. OBJECTIVES: To comprehensively describe the pattern of VWF laboratory abnormalities in the MPN population. METHODS: We collected samples from 74 unselected clinic patients with MPNs to evaluate VWF quantitatively and qualitatively via multiple methods, correlating findings with a retrospective analysis of clinical bleeding data. VWF assays were performed on both ACL TOP (Instrumentation Laboratory) and Acustar (Instrumentation Laboratory) analyzers using HemosIL reagents (Instrumentation Laboratory), along with multimer analysis by gel electrophoresis. RESULTS: Functional VWF measurements were not concordant between assays, with a median ACL TOP VWF glycoprotein IbR to antigen ratio (VWF:GPIbR/VWF:Ag) of 0.57 (IQR, 0.43-0.71) compared to a median Acustar VWF:GPIbR/VWF:Ag of 0.91 (IQR: 0.82-1.03;P < .001). The ACL TOP showed disproportionately lower results, with 73% of patients having a ratio <0.7. Despite this, no patient experienced loss of high-molecular-weight multimers by gel electrophoresis. An inverse relationship was observed between platelet count and functional ratios on both ACL TOP (R2 = 0.20; P < .001) and Acustar (R2 = 0.18; P = .0011) analyzers. While clinically significant bleeding events were relatively common (11% patients), there was no association with VWF assay abnormalities, and generally, an alternate cause(s) was identified. CONCLUSION: Discrepancies in functional VWF assays are common in patients with MPN, particularly by ACL TOP VWF:GPIbR. Based on our limited series, a VWF functional to an antigenic ratio of <0.7 ("type 2 pattern") alone is poorly predictive of bleeding risk.
引用
- Noye J, Beggs J, Mason J, et al. Discrepant low von Willebrand factor activity results on the ACL TOP analyzer are frequent in unselected patients with myeloproliferative neoplasms and show no correlation with high-molecular-weight multimer loss or bleeding phenotype. J Thromb Haemost. 2023. PMID: 38160725. doi:10.1016/j.jtha.2023.12.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。